Search - tctmd.com

Displaying 141 - 159 of 159

Sort: Relevancy | Date

Presentation ESC 2013

Incidence and Impact of Dual Antiplatelet Therapy (DAPT) Cessation on Adverse Events following Percutaneous Coronary Intervention (PCI):Results from the Real-World PARIS Registry

Presenter: 32040|Roxana Mehran

September 01, 2013

Presentation

Nuisance Bleeding with Prolonged Dual Antiplatelet Therapy After AMI and Its Impact on Health Status

Presenter: A. P. Amin

March 26, 2013

Presentation PCI Outcomes 2013

Perspectives on the Selection and Duration of Dual Antiplatelet Therapy

Presenter: Dominick J. Angiolillo

March 07, 2013

Presentation TCT 2013

Clinical impact of extended dual antiplatelet therapy after percutaneous coronary interventions in the drug-eluting stent era: a meta-analysis of randomized trials.

Presenter: Salvatore Cassese, Robert Byrne, Tomohisa Tada, Lamin King, Adnan Kastrati

January 31, 2013

Presentation TCT 2013

The REMEDEE OCT study: A prospective randomized study of the early vascular healing of a novel Dual Therapy Stent in comparison with an everolimus eluting stent

Presenter: Ulf Landmesser, William Wijns, Emanuele Barbato, Pasi Karjalainen, Robbert de Winter, Stefan Verheye, Jonathan Hill, Wojciech Wojakowski, Erik Ligtenberg, Stephen Rowland, Hiram Bezerra, Marco Costa

January 31, 2013

Presentation TCT 2013

Individual and Regional Variations in Dual Antiplatelet Therapy Dose and Duration in a Large, Randomized International Trial Comparing Two Drug-eluting Stents: Results From...

Presenter: Laura Mauri, Gabriel Steg, Alexis Matteau, Edoardo Camenzind, Eric Boersma, Pascal Vranckx, Patrick Serruys, William O'Neill, Robert Yeh, William Wijns

January 31, 2013

Presentation

Should Duration of Dual Antiplatelet Therapy Depend on the Type and/or Potency of Implanted Stent?

Presenter: Marco Valgimigli

January 16, 2013

Presentation

Benefit of Long-term Dual Antiplatelet Therapy (DAPT) in Patients Treated with DES

Presenter: Suresh R. Mulukutla

December 05, 2012

Presentation TCT 2012

"Six-Month Versus 12-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents: The Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting...

Presenter: Hyeon-Cheol Gwon

October 24, 2012

Presentation TCT 2012

"Short- Versus Long-term Duration of Dual Antiplatelet Therapy After Coronary Stenting: A Randomized Multicentre Trial." Circulation. 2012;125:2015-2026.

Presenter: Marco Valgimigli

October 24, 2012

Presentation

RESET Trial: A New Strategy for Discontinuation of Dual Antiplatelet Therapy

Presenter: B-K Kim

September 19, 2012

Presentation GI2 2012

Dual Antiplatelet Therapy Post PCI: Challenging the Guidelines

Presenter: Fausto Feres

April 13, 2012

Presentation

Short- vs. Long-term Duration of Dual Antiplatelet Therapy (DAPT) After Coronary Stenting

Presenter: Marco Valgimigli

April 02, 2012

Presentation ACC 2012

A New Strategy for Discontinuation of Dual Antiplatelet Therapy: Real Safety and Efficacy of 3-Month Dual Antiplatelet Therapy Following Zotarolimus-Eluting Stent Implantation: RESET Trial

Presenter: Myeong-Ki Hong

March 25, 2012

Presentation ISET 2012

The Value of Dual Antiplatelet Therapy During and After Endovascular Procedures: Results of a Randomized Trial - The MIRROR Study

Presenter: Gunnar Tepe

January 17, 2012

Presentation TCT 2012

Long-Term Dual Anti-Platelet Therapy in Patients Treated with Bare Metal Stent Implantation: Results From the NHLBI Dynamic Registry

Presenter: Gopi Manthripragada, Oscar C. Marroquin, Helen Vlachos, Sameer Khandhar, Catalin Toma, Joon S. Lee, David O. Williams, Kevin E. Kip, Suresh Mulukutla

January 03, 2012

Presentation TCT 2012

Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Patients with Chronic Kidney Disease: A Report From the National Heart, Lung, and Blood...

Presenter: Joseph Kim, Helen Vlachos, Suresh R. Mulukutla, Catalin Toma, Joon S. Lee, David O. Williams, Sheryl F. Kelsey, Kevin E. Kip, Oscar C. Marroquin

January 03, 2012

Presentation TCT 2012

Benefits of CD 34 Antibody Coated Stent in Patients with High Risk for Bleeding During Dual Antiplatelet Therapy.

Presenter: Miltiadis Papalexandris, Hubertus Degen, Carsten Stoepel, Thomas Lickfeld, Thorsten Schneider, Carlos Freitas, Michael Haude

January 03, 2012

Presentation TCT 2012

”Safety of Dual Antiplatelet Therapy in Patients Treated with Coronary Drug Eluting Stents.”

Presenter: Andrzej Drewnicki, Maciej Lesiak, Malgorzata Pyda, Marek Grygier, Wlodzimierz Skorupski, Aleksander Araszkiewicz, Przemyslaw Mitkowski, Stefan Grajek

January 03, 2012

Advertisement

Incidence and Impact of Dual Antiplatelet Therapy (DAPT) Cessation on Adverse Events following Percutaneous Coronary Intervention (PCI):Results from the Real-World PARIS Registry

Nuisance Bleeding with Prolonged Dual Antiplatelet Therapy After AMI and Its Impact on Health Status

Perspectives on the Selection and Duration of Dual Antiplatelet Therapy

Clinical impact of extended dual antiplatelet therapy after percutaneous coronary interventions in the drug-eluting stent era: a meta-analysis of randomized trials.

The REMEDEE OCT study: A prospective randomized study of the early vascular healing of a novel Dual Therapy Stent in comparison with an everolimus eluting stent

Individual and Regional Variations in Dual Antiplatelet Therapy Dose and Duration in a Large, Randomized International Trial Comparing Two Drug-eluting Stents: Results From...

Should Duration of Dual Antiplatelet Therapy Depend on the Type and/or Potency of Implanted Stent?

Benefit of Long-term Dual Antiplatelet Therapy (DAPT) in Patients Treated with DES

"Six-Month Versus 12-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents: The Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting...

"Short- Versus Long-term Duration of Dual Antiplatelet Therapy After Coronary Stenting: A Randomized Multicentre Trial." Circulation. 2012;125:2015-2026.

RESET Trial: A New Strategy for Discontinuation of Dual Antiplatelet Therapy

Dual Antiplatelet Therapy Post PCI: Challenging the Guidelines

Short- vs. Long-term Duration of Dual Antiplatelet Therapy (DAPT) After Coronary Stenting

A New Strategy for Discontinuation of Dual Antiplatelet Therapy: Real Safety and Efficacy of 3-Month Dual Antiplatelet Therapy Following Zotarolimus-Eluting Stent Implantation: RESET Trial

The Value of Dual Antiplatelet Therapy During and After Endovascular Procedures: Results of a Randomized Trial - The MIRROR Study

Long-Term Dual Anti-Platelet Therapy in Patients Treated with Bare Metal Stent Implantation: Results From the NHLBI Dynamic Registry

Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Patients with Chronic Kidney Disease: A Report From the National Heart, Lung, and Blood...

Benefits of CD 34 Antibody Coated Stent in Patients with High Risk for Bleeding During Dual Antiplatelet Therapy.

”Safety of Dual Antiplatelet Therapy in Patients Treated with Coronary Drug Eluting Stents.”

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content